Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin Lymphoma - PubMed
3 days ago
- #Non-Hodgkin Lymphoma
- #CAR-T therapy
- #Long-term follow-up
- Tandem CD19/CD20 CAR T cell therapy (TanCAR7) showed promising efficacy and safety in relapsed/refractory non-Hodgkin's lymphoma (r/r NHL) patients.
- Objective response rate was 78% (complete remission rate, 70%) with a median follow-up of 63.4 months.
- 40% of patients remained in remission at data cut-off.
- Estimated 5-year overall survival (OS) rate was 60.1%, with median progression-free survival (PFS) of 33 months.
- No new or unexpected TanCAR7-related serious adverse events or deaths were observed.
- High tumor burden and systemic inflammation were identified as risk factors for resistance and relapse.
- High levels of endogenous CD8+ T cells and total lymphocytes post-infusion correlated with treatment benefit.
- Salvage chemotherapy post TanCAR7 failure showed limited efficacy, while targeted therapy or secondary CAR-T cell therapy achieved responses in some patients.
- First-ever 5-year follow-up analysis demonstrates long-term remission potential and no new safety signals.